OncoSELECT is a new minimally invasive genomic study that allows to detect the mutations present in the circulating tumor DNA from a blood sample and that has three specific panels for patients with lung (NSCLC), colon or breast cancer (RH + or HER2 +).
OncoSELECT is the perfect tool for:
Based on a recent modification of the FDA guidelines, liquid biopsy is now approved as the first diagnostic tool for patients with Non-Small Cell Lung Cancer, so OncoSELECT is the perfect study to perform a first screening of the most relevant genes that are related to treatments.
OncoSELECT is unique because it focuses only on the targets that are most important in each type of cancer. It is a study focused on the essential markers of response or resistance to treatment and is currently available in three versions:
OncoSELECT is indicated in adult patients with solid tumors in lung cancer (NSCLC), colon or breast (RH + or HER2 +) in which: